Literature DB >> 25698603

A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

Jordi Boix1, Thomas Padel1, Gesine Paul2.   

Abstract

The most frequently used animal models for Parkinson's disease (PD) utilize unilateral injection of 6-hydroxydopamine (6-OHDA) in the medial forebrain bundle (MFB), which results in total denervation of the dopaminergic nigrostriatal pathway. However, neuroprotective interventions in PD require models resembling earlier stages of PD, where some dopaminergic cells and fibres remain. The aim of the present study was therefore to establish a MFB partial lesion model in mice. We tested four different 6-OHDA doses, and our results show a dose-dependent loss of nigral dopaminergic cells and striatal fibres that correlated with behavioural impairment in several behavioural tests. Specifically, doses of 0.7 μg and 1 μg of 6-OHDA induced a partial denervation of the nigrostriatal pathway, associated with a mild but quantifiable behavioural impairment. We identified the amphetamine-induced rotation, stepping, corridor and cylinder test to be sensitive enough to select partial lesion animals. Based on our data, we proposed a range of cut-off values for these different behavioural tests to select partial lesion mice. Using a statistical prediction model we identified two behavioural tests (the stepping test and amphetamine-induced rotation test) that with a high sensitivity and specificity predict the extent of nigral dopaminergic cell loss and select mice with a partial nigrostriatal lesion prior to further interventions. This model can serve as an important tool to study neuroprotective therapies for PD in mouse models, especially when the treatment targets the substantia nigra and/or the striatum.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6-Hydroxydopamine; Behavioral test; Medial forebrain bundle; Mouse model; Parkinson's disease; Prediction model

Mesh:

Substances:

Year:  2015        PMID: 25698603     DOI: 10.1016/j.bbr.2015.01.053

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  48 in total

1.  Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.

Authors:  Chi Wang Ip; Sandra K Beck; Jens Volkmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-20       Impact factor: 3.575

2.  Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons.

Authors:  Nicola L Francis; Nanxia Zhao; Hannah R Calvelli; Astha Saini; Janace J Gifford; George C Wagner; Rick I Cohen; Zhiping P Pang; Prabhas V Moghe
Journal:  Tissue Eng Part A       Date:  2019-10-17       Impact factor: 3.845

3.  Post 6-OHDA lesion exposure to stress affects neurotrophic factor expression and aggravates motor impairment.

Authors:  Phumzile Nomfundo Ngema; Musa Vuyisile Mabandla
Journal:  Metab Brain Dis       Date:  2017-03-20       Impact factor: 3.584

4.  The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.

Authors:  Piniel Alphayo Kambey; Ma Chengcheng; Guo Xiaoxiao; Ayanlaja Abiola Abdulrahman; Kouminin Kanwore; Iqra Nadeem; Wu Jiao; Dianshuai Gao
Journal:  Metab Brain Dis       Date:  2021-01-28       Impact factor: 3.584

Review 5.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

6.  Cylinder Test to Assess Sensory-motor Function in a Mouse Model of Parkinson's Disease.

Authors:  Luiz Alexandre Viana Magno; Mélcar Collodetti; Helia Tenza-Ferrer; Marco Aurélio Romano-Silva
Journal:  Bio Protoc       Date:  2019-08-20

7.  Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments.

Authors:  Yuan Cai; Beatriz E Nielsen; Emma E Boxer; Jason Aoto; Christopher P Ford
Journal:  Neuron       Date:  2021-02-17       Impact factor: 17.173

8.  Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.

Authors:  Yoshitsugu Nakamura; Shigeki Arawaka; Hiroyasu Sato; Asuka Sasaki; Taro Shigekiyo; Kazue Takahata; Hiroko Tsunekawa; Takeo Kato
Journal:  J Neurosci       Date:  2021-07-21       Impact factor: 6.167

9.  A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms.

Authors:  Débora Masini; Carina Plewnia; Maëlle Bertho; Nicolas Scalbert; Vittorio Caggiano; Gilberto Fisone
Journal:  Biomedicines       Date:  2021-05-25

10.  In Vivo Assessment of Cell Death and Nigrostriatal Pathway Integrity Following Continuous Expression of C3 Transferase.

Authors:  Rohan V Gupta; Angel J Santiago-Lopez; Ken Berglund; Robert E Gross; Claire-Anne N Gutekunst
Journal:  Neuroscience       Date:  2020-07-09       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.